Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Cooperation possibilities

The company has several programs that offer significant partnering opportunities. The proprietary drug discovery platform technology Magellan™ can also provide partnering opportunities for the discovery of novel brain-penetrant small molecules against novel selected targets.

Some insights
Location
Canton
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    1-9

You may also be interested in